Growth hormone supplementation increased latency to tumourigenesis in Atm-deficient mice

Growth Factors

Volumn 27, Issue 5, 2009, Pages 265-273

  Schubert, Ralf ^a   Schmitz, Nathalie ^a   Pietzner, Julia ^a   Tandi, Christa ^a   Theisen, Alf ^a   Dresel, Ruth ^a   Christmann, Martin ^a   Zielen, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Ataxia telangiectasia; Growth hormone; Tumourigenesis

Indexed keywords

ATM PROTEIN; GROWTH HORMONE; METHIONINE DERIVATIVE; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA TELANGIECTASIA; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CELLULAR IMMUNITY; CHROMOSOMAL INSTABILITY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG FATALITY; DRUG MECHANISM; ENZYME DEFICIENCY; FEMALE; FOOD INTAKE; GROWTH HORMONE BLOOD LEVEL; HORMONAL CARCINOGENESIS; HORMONAL THERAPY; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; LATENT PERIOD; LOCOMOTION; LONGEVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; THYMUS LYMPHOMA; TUMOR IMMUNITY; WEIGHT GAIN; WILD TYPE;

ANIMALS; ATAXIA TELANGIECTASIA; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; GROWTH HORMONE; HUMANS; LYMPHOMA; MALE; MICE; PROTEIN-SERINE-THREONINE KINASES; RATS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; THYMUS NEOPLASMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA; MUS;

EID: 70349427141     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.1080/08977190903112663     Document Type: Article

References (52)

1. Bagley J, Cortes ML, Breakefield XO, Iacomini J. 2004. Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice. Blood 104:572-578.
2. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw-Boris A. 1996. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 86:159-171.
3. Binder G, Neuer K, Ranke MB, Wittekindt NE. 2005. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 90:5377-5381.
4. Boder E, Sedgwick RP. 1958. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 21: 526-554.
5. Browne SE, Roberts LJ, 2nd, Dennery PA, Doctrow SR, Beal MF, Barlow C, Levine RL. 2004. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxiatelangiectasia mice. Free Radic Biol Med 36:938-942.
6. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649.
7. Butturini A, Bernasconi S, Izzi G, Gertner JM, Gale RP. 1994. Short stature, Fanconi's anaemia, and risk of leukaemia after growth hormone therapy. Lancet 343:1576.
8. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. 1998. Plasma insulinlike growth factor-I and prostate cancer risk: A prospective study. Science 279:563-566.
9. Chen P, Peng C, Luff J, Spring K, Watters D, Bottle S, Furuya S, Lavin MF. 2003. Oxidative stress is responsible for deficient survival and dendritogenesis in purkinje neurons from ataxiatelangiectasia mutated mutant mice. J Neurosci 23: 11453-11460.
10. Clark R. 1997. The somatogenic hormones and insulin-like growth factor-1: Stimulators of lymphopoiesis and immune function. Endocr Rev 18:157-179.
11. Clark RG. 2004. Recombinant human insulin-like growth factor I (IGF-I): Risks and benefits of normalizing blood IGF-I concentrations. Horm Res 62:93-100.
12. Clayton PE, Freeth JS, Whatmore AJ, Ayling RM, Norman MR, Silva CM. 1999. Signal transduction defects in growth hormone insensitivity. Acta Paediatr Suppl 88:174-178.
13. Csiszar A, Labinskyy N, Perez V, Recchia FA, Podlutsky A, Mukhopadhyay P, Losonczy G, Pacher P, Austad SN, Bartke A, Ungvari Z. 2008. Endothelial function and vascular oxidative stress in long-lived GH/ IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol 295:1882-1894.
14. D'Ercole AJ, Ye P, O'Kusky JR. 2002. Mutant mouse models of insulin-like growth factor actions in the central nervous system. Neuropeptides 36:209-220.
15. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. 2006. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 91:3494-3498.
16. Erker L, Schubert R, Yakushiji H, Barlow C, Larson D, Mitchell JB, Wynshaw-Boris A. 2005. Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumour suppressor. Hum Mol Genet 14:1699-1708.
17. Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. 1991. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol 9:394-399.
18. Farris GM, Miller GK, Wollenberg GK, Molon-Noblot S, Chan C, Prahalada S. 2007. Recombinant rat and mouse growth hormones: Risk assessment of carcinogenic potential in 2-year bioassays in rats and mice. Toxicol Sci 97:548-561.
19. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. 1998. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396.
20. Hinkal G, Donehower LA. 2008. How does suppression of IGF-1 signaling by DNA damage affect aging and longevity. Mech Ageing Dev 129:243-253.
21. Hishiya A, Ito M, AburataniH,Motoyama N, Ikeda K,Watanabe K. 2005. Ataxia telangiectasia mutated (Atm) knockout mice as a model of osteopenia due to impaired bone formation. Bone 37: 497-503.
22. Homayoun P, Daher R, van Lente F, Faiman C, Gupta MK. 1996. Immunoradiometric assay measurements of insulin-like growth factor-I (IGF-I): Comparison with radioimmunoassays using native or des (1-3) IGF-I as radioligands. J Clin Lab Anal 10: 446-450.
23. Hwang DL, Lee PD, Cohen P. 2008. Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. Growth Horm IGF Res 18:65-74.
24. Isgaard J, Aberg D, Nilsson M. 2007. Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol 32:103-113.
25. Knyszynski A, Adler-Kunin S, Globerson A. 1992. Effects of growth hormone on thymocyte development from progenitor cells in the bone marrow. Brain Behav Immun 6:327-340.
26. Lamine F, Turki Z, Mrad R, Ben Salem L, Ben Hafsa I, Akrout S, Ben Slama C. 2008. Growth hormone deficiency and pituitary stalk interruption in Fanconi anemia. Ann Endocrinol (Paris) 69:63-68.
27. Lavin MF. 2008. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9:759-769.
28. Lavin MF, Gueven N, Bottle S, Gatti RA. 2007. Current and potential therapeutic strategies for the treatment of ataxiatelangiectasia. Br Med Bull 81-82:129-147.
29. Levine AJ, Feng Z, Mak TW, You H, Jin S. 2006. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20:267-275.
30. Lijffijt M, Van Dam PS, Kenemans JL, Koppeschaar HP, de Vries WR, Drent ML, Wittenberg A, Kemner C. 2003. Somatotropic-axis deficiency affects brain substrates of selective attention in childhood-onset growth hormone deficient patients. Neurosci Lett 353:123-126.
31. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625.
32. Montecino-Rodriguez E, Clark R, Dorshkind K. 1998. Effects of insulin-like growth factor administration and bone marrow transplantation on thymopoiesis in aged mice. Endocrinology 139:4120-4126.
33. Murphy WJ, Durum SK, Anver M, Frazier M, Longo DL. 1992. Recombinant human growth hormone promotes human lymphocyte engraftment in immunodeficient mice and results in an increased incidence of human Epstein Barr virus-induced B-cell lymphoma. Brain Behav Immun 6:355-364.
34. Napolitano LA, Schmidt D, Gotway MB, Ameli N, Filbert EL, Ng MM, Clor JL, Epling L, Sinclair E, Baum PD, Li K, Killian ML, Bacchetti P, McCune JM. 2008. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 118: 1085-1098.
35. Ogilvy-Stuart AL, Gleeson H. 2004. Cancer risk following growth hormone use in childhood: Implications for current practice. Drug Saf 27:369-382.
36. Packer RJ, Boyett JM, Janss AJ, Stavrou T, Kun L, Wisoff J, Russo C, Geyer R, Phillips P, Kieran M, Greenberg M, Goldman S, Hyder D, Heideman R, Jones-Wallace D, August GP, Smith SH, Moshang T. 2001. Growth hormone replacement therapy in children with medulloblastoma: Use and effect on tumour control. J Clin Oncol 19:480-487.
37. Peretz S, Jensen R, Baserga R, Glazer PM. 2001. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci USA 98:1676-1681.
38. Reliene R, Schiestl RH. 2007. Antioxidants suppress lymphoma and increase longevity in Atm-deficient mice. J Nutr 137: 229S-232S.
39. Rogers PC, Komp D, Rogol A, Sabio H. 1977. Possible effects of growth hormone on development of acute lymphoblastic leukaemia. Lancet 2:434-435.
40. Scacchi M, Valassi E, Pincelli AI, Fatti LM, Pecori Giraldi F, Ascoli P, Viarengo R, Cestaro B, Cavagnini F, Cazzola R. 2006. Increased lipid peroxidation in adult GH-deficient patients: Effects of short-termGHadministration. J Endocrinol Invest 29: 899-904.
41. Schubert R, Reichenbach J, Zielen S. 2002. Deficiencies in CD4+ and CD8+T cell subsets in ataxia telangiectasia. Clin Exp Immunol 129:125-132.
42. Schubert R, Erker L, Barlow C, Yakushiji H, Larson D, Russo A, Mitchell JB, Wynshaw-Boris A. 2004. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet 13:1793-1802.
43. Schubert R, Reichenbach J, Zielen S. 2005. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol 140:517-519.
44. Seiva FRF, Ebaid GMX, Castro AVB, Okoshi K, Nascimento A, Rocha KKH, Padovani CR, Cicogna AC, Novelli EL. 2008. Growth hormone and heart failure: Oxidative stress and energetic metabolism in rats. Growth Horm IGF Res 18: 275-283.
45. Shahrabani-Gargir L, Pandita TK, Werner H. 2004. Ataxia telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 145:5679-5687.
46. Stahnke N. 1992. Leukemia in growth-hormone-treated patients: An update, 1992. Horm Res 38:56-62.
47. Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Ogura T, Lavin MF, Esumi H. 2004. IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem Biophys Res Commun 324:986-992.
48. Swift M, Morrell D, Massey RB, Chase CL. 1991. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325:1831-1836.
49. Taha DR, Bastian W, Castells S. 2001. Growth hormone replacement therapy in children with leukemia in remission. Clin Pediatr 40:441-445.
50. Tresguerres JAF, Kireev R, Tresguerres AF, Borras C, Vara E, Ariznavarreta C. 2008. Molecular mechanisms involved in the hormonal prevention of aging in the rat. J Steroid Biochem Mol Biol 108:318-326.
51. Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M, Seely BL. 1996. Repression of the insulin receptor promoter by the tumour suppressor gene product p53: A possible mechanismfor receptor overexpression in breast cancer. Cancer Res 56:2781-2788.
52. Yang DQ, Kastan MB. 2000. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2:893-898.